We are thrilled to let you know that starting April 6, HAEGARDA, a subcutaneous C1 Esterase Inhibitor (human), manufactured by CSL Behring, will be included on the Canadian Blood Services (CBS) formulary. This means that all eligible HAE patients across Canada will be able to access this treatment.
For further details, please CLICK HERE for the announcement from CSL Behring.
This accomplishment did not happen over night; there were many steps taken to reach this amazing point in the road. We are proud that HAE Canada was part of one of these steps by providing a Patient Submission to CBS to help illustrate the importance this treatment is for patients. We want to extend a huge thank you to all our members who participate in our surveys; the data we collect is used to develop our submissions.
We want to thank the team at CSL Behring who worked extremely hard to bring this treatment to Canadian HAE patients. We are truly grateful for their dedication and commitment. Also, we want to thank the team at CBS who gave HAE Canada the opportunity to advocate for HAE patients across the country. Thank you for listening to patients who shared their stories and experiences and for ultimately adding this treatment to the CBS formulary, allowing equitable access to patients across Canada.
Please CLICK HERE to view CBS’s Dear Customer Letter (DCL) on their website, indicating that healthcare providers will be able to prescribe HAEGARDA for HAE patients beginning the week of April 6th, 2021, using the “Factor Concentrates & Other Plasma Protein Order Form”.